Legend Biotech (LEGN) Total Debt (2021 - 2026)
Legend Biotech's (LEGN) quarterly Total Debt came in at $266.0 million in Q1 2026, down 13.0% YoY from $305.7 million in Q1 2025, and down 58.32% on a QoQ basis from $638.2 million in Q4 2025.
Legend Biotech (LEGN) Total Debt (2021 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 6 years of Total Debt data on file, last reported at $266.0 million in Q1 2026.
- Quarterly Total Debt fell 13.0% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (down 13.0% YoY) and the FY2025 annual result came in at $638.2 million, up 111.89% from the prior year.
- Total Debt eased to $266.0 million in Q1 2026, from $638.2 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $638.2 million in Q4 2025 to a low of $253.4 million in Q1 2022.
- A 5-year average of $307.9 million and a median of $286.4 million in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2025 — Total Debt surged 111.89% — and 2026, when it retreated 13.0%.
- Tracing LEGN's Total Debt over 5 years: stood at $260.9 million in 2022, then rose by 7.82% to $281.3 million in 2023, then climbed by 7.06% to $301.2 million in 2024, then surged by 111.89% to $638.2 million in 2025, then plunged by 58.32% to $266.0 million in 2026.
- The last three Total Debt figures came in at $266.0 million (Q1 2026), $638.2 million (Q4 2025), and $314.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 156.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.40 Mn |
| Mar 31, 2026 | 266.00 Mn |
| Dec 31, 2025 | 638.20 Mn |
| Sep 30, 2025 | 314.83 Mn |
| Jun 30, 2025 | 310.26 Mn |
| Mar 31, 2025 | 305.75 Mn |
| Dec 31, 2024 | 301.20 Mn |
| Sep 30, 2024 | 296.62 Mn |
| Jun 30, 2024 | 291.56 Mn |
| Mar 31, 2024 | 286.40 Mn |
| Dec 31, 2023 | 281.33 Mn |
| Sep 30, 2023 | 275.91 Mn |
| Jun 30, 2023 | 270.61 Mn |
| Mar 31, 2023 | 265.86 Mn |
| Dec 31, 2022 | 260.93 Mn |
| Mar 31, 2022 | 253.43 Mn |
| Dec 31, 2021 | 240.92 Mn |
| Sep 30, 2021 | 70.54 Mn |
| Jun 30, 2021 | 34.62 Mn |